Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

Morgan Stanley initiated coverage of Roche (RHHBY) with an Equal Weight rating and CHF 305 price target The firm sees the end of Roche’s ...

The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 ...

The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Companion Diagnostics Market Companion Diagnostics Market Dublin, Feb. 13, 2025 (GLOBE NEWSWIRE) -- The "Companion ...